Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKLIEF vs BYQLOVI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AKLIEF (trifarotene) is a selective retinoic acid receptor (RAR) gamma agonist. It modulates gene expression by binding to RAR-gamma, leading to normalization of follicular keratinization, reduced comedogenesis, and anti-inflammatory effects.
BYQLOVI (revumenib) is a menin inhibitor that binds to the menin protein, blocking its interaction with mixed lineage leukemia (MLL) fusion proteins and thus inhibiting leukemogenesis.
FDA-approved for the topical treatment of acne vulgaris in patients 9 years of age and older
Treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A (KMT2A) gene translocation in adults and pediatric patients 1 year and older
Apply a thin layer to affected areas once daily in the evening, avoiding eyes, lips, and mucous membranes.
BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is administered orally as a single tablet (50/200/25 mg) once daily with or without food.
Terminal elimination half-life: ~29 hours after topical application; supports once-daily dosing.
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in patients with normal renal function; prolonged in renal impairment.
Trifarotene is metabolized primarily via CYP2D6 and to a lesser extent via CYP3A4. It undergoes extensive first-pass metabolism with low systemic exposure after topical application.
Primarily metabolized by CYP3A4 and CYP2D6.
Fecal: ~70% as unchanged drug; Renal: <1% as metabolites.
Renal excretion of unchanged drug accounts for approximately 95% of elimination; fecal excretion is minimal (<5%).
>99% bound to plasma proteins (primarily albumin and lipoproteins).
Approximately 85% bound to serum albumin.
Not determined for topical route; systemic absorption minimal with Vd not clinically relevant.
Volume of distribution is about 0.6 L/kg, indicating distribution into total body water.
Topical: ~1% systemic absorption; oral: not applicable.
Oral bioavailability is approximately 80% (range 75–85%) under fasting conditions; food may reduce absorption.
No dose adjustment required in renal impairment. Not studied in severe renal impairment.
Contraindicated in patients with estimated creatinine clearance (Cr Cl) <30 m L/min. No dose adjustment required for Cr Cl ≥30 m L/min.
No dose adjustment required in mild to moderate hepatic impairment (Child-Pugh A, B). Not studied in severe hepatic impairment (Child-Pugh C).
Not recommended in patients with severe hepatic impairment (Child-Pugh Class C). No dose adjustment required for mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.
Approved for acne vulgaris in patients aged 12 years and older: apply a thin layer to affected areas once daily in the evening.
For adolescents aged ≥12 years and weighing ≥35 kg, administer one tablet (50/200/25 mg) orally once daily. Safety and efficacy not established in pediatric patients <12 years or <35 kg.
No specific dose adjustment required; clinical studies did not include sufficient geriatric patients to determine differential response.
No specific dose adjustment recommended in elderly patients. Monitor renal function due to age-related decline.
None.
No FDA boxed warning reported.
Local skin reactions (erythema, scaling, dryness, stinging/burning) may occur; reduce frequency or discontinue if severe.,Avoid excessive exposure to sunlight or UV light; use sunscreens and protective clothing.,Avoid contact with eyes, mouth, angles of the nose, and mucous membranes.,Pregnancy: Limited data; no known risk of major malformations based on animal studies, but use only if clearly needed.
Differentiation syndrome, which may be life-threatening or fatal; if suspected, initiate corticosteroids and hemodynamic monitoring.,QTc interval prolongation; monitor electrolytes and electrocardiograms.,Embryo-fetal toxicity.
Hypersensitivity to trifarotene or any component of the formulation
None reported.
No significant food interactions reported. Avoid excessive alcohol consumption as it may exacerbate skin dryness and irritation. No specific dietary restrictions.
Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit as they inhibit CYP3A4 and can increase drug levels, leading to toxicity. No other known food interactions. Take with or without food, but consistent timing and fat content is recommended to maintain stable exposure.
Pregnancy Category C. First trimester: No adequate studies in humans; animal studies show embryofetal toxicity at high doses. Risk cannot be ruled out. Second and third trimesters: Limited data; avoid unless benefit outweighs risk.
BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is contraindicated in pregnancy due to risk of neural tube defects (NTDs) observed with dolutegravir-containing regimens in first trimester exposure. In animal studies, no evidence of teratogenicity at clinically relevant exposures. Human data: insufficient for risk assessment; case reports of NTDs with bictegravir insufficient to rule out. First trimester: potential for NTDs, avoid unless benefit outweighs risk. Second/third trimester: limited data, no specific fetal risks identified, but use alternative if possible.
No data on excretion in human milk; M/P ratio unknown. Caution advised due to potential for serious adverse reactions in nursing infants.
Breastfeeding not recommended during BYQLOVI therapy due to potential for HIV-1 transmission via breast milk and unknown effects in infants. Bictegravir excretion into human milk unknown; emtricitabine: M/P ratio ~0.6; tenofovir alafenamide: M/P ratio ~0.3 (tenofovir). Limited data: low levels may be excreted. HIV-positive mothers should not breastfeed to avoid transmission.
No specific dose adjustments recommended; pharmacokinetic changes in pregnancy unknown. Use lowest effective dose if necessary.
No specific dosing adjustments recommended during pregnancy due to limited data. Pharmacokinetic studies in pregnancy are lacking. Bictegravir AUC may decrease in second and third trimester; clinical relevance unknown. Consider alternative antiretroviral regimens with established safety data in pregnancy (e.g., dolutegravir plus emtricitabine/tenofovir disoproxil fumarate).
AKLIEF (trifarotene) is a fourth-generation retinoid selective for RAR-γ receptors, minimizing irritation compared to tretinoin. Use pea-sized amount for entire face; avoid excessive application. Initiate every other night to improve tolerability. Concomitant use of benzoyl peroxide or salicylic acid may increase dryness; advise non-comedogenic moisturizers. Contraindicated in pregnancy (Category X); rule out pregnancy before starting.
BYQLOVI (bruton tyrosine kinase inhibitor) is indicated for chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia. Monitor for atrial fibrillation, hypertension, and bleeding risk. Administer with a full glass of water and do not crush or open capsules. Dose reduction may be needed with strong CYP3A4 inhibitors. Avoid concurrent use with warfarin or other anticoagulants if possible.
Apply a thin layer once daily at night to clean, dry skin.,Avoid sun exposure and use broad-spectrum SPF 30+ sunscreen daily.,May cause initial redness, peeling, and dryness; use moisturizer.,Do not use if pregnant or planning pregnancy; use effective contraception.,Do not apply to cuts, abrasions, or eczematous skin.,Avoid waxing or laser hair removal during treatment.,Therapeutic effect may take 8-12 weeks.,Keep out of reach of children and away from eyes, mouth, and mucous membranes.
Take exactly as prescribed, with a full glass of water.,Do not open, break, or chew the capsules; swallow whole.,Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit while on this medication.,Report any signs of bleeding (e.g., unusual bruising, black stools) or irregular heartbeat immediately.,Avoid activities that may cause injury due to increased bleeding risk.,Use effective contraception during treatment and for at least 1 month after the last dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKLIEF vs BYQLOVI, answered by our medical review team.
AKLIEF is a Topical Retinoid that works by AKLIEF (trifarotene) is a selective retinoic acid receptor (RAR) gamma agonist. It modulates gene expression by binding to RAR-gamma, leading to normalization of follicular keratinization, reduced comedogenesis, and anti-inflammatory effects.. BYQLOVI is a Topical Retinoid that works by BYQLOVI (revumenib) is a menin inhibitor that binds to the menin protein, blocking its interaction with mixed lineage leukemia (MLL) fusion proteins and thus inhibiting leukemogenesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKLIEF and BYQLOVI depend on the specific clinical indication. These are both Topical Retinoid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKLIEF is: Apply a thin layer to affected areas once daily in the evening, avoiding eyes, lips, and mucous membranes.. The standard adult dose of BYQLOVI is: BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is administered orally as a single tablet (50/200/25 mg) once daily with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKLIEF and BYQLOVI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKLIEF is classified as Category C. Pregnancy Category C. First trimester: No adequate studies in humans; animal studies show embryofetal toxicity at high doses. Risk cannot be ruled out. Second and third trimesters:. BYQLOVI is classified as Category C. BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is contraindicated in pregnancy due to risk of neural tube defects (NTDs) observed with dolutegravir-containing regimens i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.